Reference pricing systems on the pharmaceutical market

References

Brekke, K., T. H. Holmås, and O. R. Straume. 2011. “Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment.” Journal of Public Economics 95:624–638. 10.1016/j.jpubeco.2010.11.015Search in Google Scholar

Brekke, K., I. Königbauer, and O. R. Straume. 2007. “Reference Pricing of Pharmaceuticals.” Journal of Health Economics 26:613–642. 10.1016/j.jhealeco.2006.11.003Search in Google Scholar

Brekke, K. R., C. Canta, and O. R. Straume. 2016. “Reference Pricing with Endogenous Generic Entry.” Journal of Health Economics 50:312–329. 10.1016/j.jhealeco.2016.04.003Search in Google Scholar

Brekke, K. R., A. L. Grasdal, and T. H. Holmås. 2009. “Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?” European Economic Review 53:170–185. 10.1016/j.euroecorev.2008.03.004Search in Google Scholar

Bundesgesundheitsministerium. 2016. “Arzneimittelmarktneuordnungsgesetz (AMNOG).” Accessed May 28, 2019. https://www.bundesgesundheitsministerium.de/service/begriffe-von-a-z/a/arzneimittelmarktneuordnungsgesetz-amnog.html. Search in Google Scholar

Bundesgesundheitsministerium. 2019. “Zuzahlung und Erstattung von Arzneimitteln.” Accessed May 28, 2019. https://www.bundesgesundheitsministerium.de/zuzahlung-und-erstattung-arzneimittel.html#c2795. Search in Google Scholar

Dalen, D., S. Strøm, and T. Haabeth. 2006. “Price Regulation and Generic Competition in the Pharmaceutical Market.” The European Journal of Health Economics 7(3): 208–214. 10.1007/s10198-006-0357-ySearch in Google Scholar

Danzon, P., and J. Ketcham. 2004. “Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand.” Forum for Health Economics and Policy 7. 10.3386/w10007Search in Google Scholar

Dingermann, T. 2013. “Das Arzneimittelmarktneuordnungsgesetz (AMNOG) und seine Folgen.” Internist 54:769–774. 10.1007/s00108-013-3247-2Search in Google Scholar

Drummond, M., B. Jönsson, F. Rutten, and T. Stargardt. 2010. “Reimbursement of Pharmaceuticals: Reference Pricing Versus Health Technology Assessment.” The European Journal of Health Economics 12(3): 263–271. 10.1007/s10198-010-0274-ySearch in Google Scholar

Farfan-Portet, M.-I., C. V. de Voorde, F. Vrijens, and R. V. Stichele. 2012. “Patient Socioeconomic Determinants of the Choice of Generic Versus Brand Name Drugs in the Context of a Reference Price System: Evidence from Belgian Prescription Data.” The European Journal of Health Economics 13(3): 301–313. 10.1007/s10198-012-0377-8Search in Google Scholar

Frank, R. G., and D. S. Salkever. 1997. “Generic Entry and the Pricing of Pharmaceuticals.” Journal of Economics and Management Strategy 6:75–90. 10.3386/w5306Search in Google Scholar

Grabowski, H. G., and J. M. Vernon. 1992. “Brand Loyalty, Entry, and Price Competition in Pharmaceuticals After the 1984 Drug Act.” Journal of Law and Economics 35(2): 1137–1149. 10.1086/467257Search in Google Scholar

Herr, A., T. Stühmeier, and T. Wenzel. 2014. “Reference Pricing and Cost-sharing: Theory and Evidence on German Off-patent Drugs.” Beiträge zur Jahrestagung des Vereins für Socialpolitik 2014. Search in Google Scholar

Herr, A., and M. Suppliet. 2011. Pharmaceutical Prices Under Regulation: Tiered Co-payments and Reference Pricing in Germany. DICE Discussion Papers, 48. Search in Google Scholar

Kaiser, U., S. Mendez, and T. Rønde. 2014. “Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark.” Journal of Health Economics 36:174–187. 10.1016/j.jhealeco.2014.04.003Search in Google Scholar

Königbauer, I. 2006. “Dealing with Rising Health Care Costs: The Case of Pharmaceuticals.” Inaugural-Dissertation. Search in Google Scholar

López-Casanovas, G., and J. Puig-Junoy. 2000. “Review of the Literature on Reference Pricing.” Health Policy 54(2): 87–123. 10.1016/S0168-8510(00)00100-7Search in Google Scholar

Miraldo, M. 2007. “Reference Pricing Versus Co-payment in the Pharmaceutical Industry: Price, Quality and Market Coverage.” CHE Research Paper, 25. Search in Google Scholar

Pavenik, N. 2002. “Do Pharmaceutical Prices Respond to Potential Patient Out-of-pocket Expenses?” The Rand Journal of Economics 33(3): 469–487. 10.2307/3087468Search in Google Scholar

Podnar, K., B. Molji, and U. Golob. 2007. “How Reference Pricing for Pharmaceuticals Can Increase Generic Share of Market: The Slovenian Experience.” Journal of Public Policy and Marketing 26(1): 89–101. 10.1509/jppm.26.1.89Search in Google Scholar

Puig-Junoy, J. 2005. “The Impact of Generic Reference Pricing Interventions in the Statin Market.” Health Policy 1(84): 14–29. 10.2139/ssrn.1001653Search in Google Scholar

Scherer, F. M. 1993. “Pricing, Profits, and Technological Progress in the Pharmaceutical Industry.” Journal of Economic Perspectives 7(3): 97–115. 10.1257/jep.7.3.97Search in Google Scholar

Schöffski, O., F.-U. Fricke, and W. Guminski. 2008. Das Krankenversicherungssystem in Deutschland, Berlin: Springer. Search in Google Scholar

Unsorg, M. 2018. “Reference Pricing Systems on the Pharmaceutical Market.” Working Papers in Economics and Finance, 115. Search in Google Scholar

Verband forschender Arzneimittelhersteller e. V. 2015. “Patente Für Arzneimittel.” Accessed May 28, 2019. https://www.vfa.de/de/arzneimittel-forschung/artikel-arzneimittel-forschung/patentschutz.html. Search in Google Scholar